| Autor: |
Biedenbach, D. J., Bouchillon, S. K., Hackel, M., Miller, L. A., Scangarella-Oman, N. E., Jakielaszek, C., Sahm, D. F. |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; February 2016, Vol. 60 Issue: 3 p1918-1923, 6p |
| Abstrakt: |
ABSTRACTGepotidacin inhibits bacterial DNA replication through a mode different from that of fluoroquinolones. Gepotidacin and comparators were tested by broth and agar dilution against clinical isolates. The in vitroactivities of gepotidacin were comparable against methicillin-susceptible and -resistant Staphylococcus aureus(MSSA and MRSA, respectively) isolates (MIC90, 0.5 μg/ml). The gepotidacin MIC90s were as follows (in micrograms per milliliter) for the indicated bacteria: Streptococcus pyogenes, 0.25; Escherichia coli, 2; Moraxella catarrhalis, ≤0.06; Streptococcus pneumoniae(0.25), Haemophilus influenzae, 1; Clostridium perfringens, 0.5; and Shigellaspp., 1, including levofloxacin-resistant subsets. Gepotidacin warrants further investigation for clinical development. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
